Skip to main
IMRX
IMRX logo

Immuneering Corp (IMRX) Stock Forecast & Price Target

Immuneering Corp (IMRX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immuneering Corp has demonstrated significant advancements in patient outcomes, highlighted by improved overall survival (OS) and progression-free survival (PFS) rates when compared to current standard of care (SoC) therapies, as evidenced by their ongoing clinical trials. The favorable safety profile and tolerability of their therapy, atebimetinib, along with the modified GnP regimen, provide a competitive edge over existing treatments, which enhances the company's overall appeal in the biopharmaceutical sector. Additionally, encouraging case studies have shown remarkable patient responses, indicating the potential for innovative treatment options and solidifying Immuneering's position within the oncology market.

Bears say

The financial outlook for Immuneering Corp appears negative due to significant regulatory risks associated with its product approvals, which could lead to adverse adjustments in risk-adjusted projections and overall valuations. The company's reliance on the performance of IMM-1-104 presents additional concerns; if it fails to demonstrate improved efficacy or tolerability compared to existing therapies, it could further impact financial estimates negatively. Additionally, the potential need for further capital raises to achieve profitability raises the risk of share dilution for current shareholders, compounding the challenges faced by the company in the competitive biopharmaceutical landscape.

Immuneering Corp (IMRX) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immuneering Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immuneering Corp (IMRX) Forecast

Analysts have given Immuneering Corp (IMRX) a Buy based on their latest research and market trends.

According to 6 analysts, Immuneering Corp (IMRX) has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immuneering Corp (IMRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.